Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Agreement
Neuraxpharm and Pharmathen Enter into Agreement to Develop Long-acting Therapies
Details : The agreement aims to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Partners Group
Deal Size : $1,900.0 million
Deal Type : Acquisition
Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners
Details : Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 19, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Partners Group
Deal Size : $1,900.0 million
Deal Type : Acquisition
Reset All
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
